NASDAQ:BPMC - Blueprint Medicines Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $56.24 +0.08 (+0.14 %) (As of 12/17/2018 02:18 AM ET)Previous Close$56.24Today's Range$53.66 - $56.8452-Week Range$50.51 - $109.00Volume381,474 shsAverage Volume291,285 shsMarket Capitalization$2.47 billionP/E Ratio-14.35Dividend YieldN/ABeta1.42 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. Receive BPMC News and Ratings via Email Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC Previous Symbol CUSIPN/A Webwww.blueprintmedicines.com Phone617-374-7580 Debt Debt-to-Equity Ratio0.03 Current Ratio10.05 Quick Ratio10.05 Price-To-Earnings Trailing P/E Ratio-14.35 Forward P/E Ratio-10.71 P/E GrowthN/A Sales & Book Value Annual Sales$21.43 million Price / Sales115.18 Cash FlowN/A Price / Cash FlowN/A Book Value$14.55 per share Price / Book3.87 Profitability EPS (Most Recent Fiscal Year)($3.92) Net Income$-148,110,000.00 Net Margins-455.15% Return on Equity-36.72% Return on Assets-30.98% Miscellaneous Employees149 Outstanding Shares43,890,000Market Cap$2.47 billion OptionableOptionable Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings data on Tuesday, October, 30th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.57) by $0.09. The biotechnology company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.87 million. Blueprint Medicines had a negative return on equity of 36.72% and a negative net margin of 455.15%. Blueprint Medicines's quarterly revenue was down 86.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.96) earnings per share. View Blueprint Medicines' Earnings History. When is Blueprint Medicines' next earnings date? Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Blueprint Medicines. What price target have analysts set for BPMC? 5 equities research analysts have issued twelve-month price targets for Blueprint Medicines' shares. Their predictions range from $101.00 to $105.00. On average, they anticipate Blueprint Medicines' stock price to reach $102.75 in the next year. This suggests a possible upside of 82.7% from the stock's current price. View Analyst Price Targets for Blueprint Medicines. What is the consensus analysts' recommendation for Blueprint Medicines? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines. Has Blueprint Medicines been receiving favorable news coverage? Media headlines about BPMC stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Blueprint Medicines earned a daily sentiment score of 1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are some of Blueprint Medicines' key competitors? Some companies that are related to Blueprint Medicines include Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Ionis Pharmaceuticals (IONS), Nektar Therapeutics (NKTR), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT) and Amneal Pharmaceuticals (AMRX). Who are Blueprint Medicines' key executives? Blueprint Medicines' management team includes the folowing people: Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 47)Mr. Alexis A. Borisy, Co-Founder & Director (Age 46)Mr. Michael Landsittel, VP of Fin. (Age 46)Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 55)Ms. Kathryn Haviland, Chief Bus. Officer (Age 42) When did Blueprint Medicines IPO? (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Vanguard Group Inc. (8.51%), Vanguard Group Inc (8.51%), BlackRock Inc. (7.86%), Partner Fund Management L.P. (3.28%) and Alliancebernstein L.P. (2.34%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin, Nicholas Lydon and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines. Which major investors are selling Blueprint Medicines stock? BPMC stock was sold by a variety of institutional investors in the last quarter, including Artal Group S.A., Morgan Stanley, Deutsche Bank AG, Foresite Capital Management III LLC, Opaleye Management Inc., Sofinnova Ventures Inc, Man Group plc and Perceptive Advisors LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines. Which major investors are buying Blueprint Medicines stock? BPMC stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Partner Fund Management L.P., Carillon Tower Advisers Inc., Alliancebernstein L.P., Marshall Wace LLP, BlackRock Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for Blueprint Medicines. How do I buy shares of Blueprint Medicines? Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $56.24. How big of a company is Blueprint Medicines? Blueprint Medicines has a market capitalization of $2.47 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe. What is Blueprint Medicines' official website? The official website for Blueprint Medicines is http://www.blueprintmedicines.com. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected] MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 312 (Vote Outperform)Underperform Votes: 204 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?